A 21-year old woman was resistant to prednisolone, mesalamine, infliximab, ustekinumab, ozanimod, filgotinib, vedolizumab, upadacitinib, cyclosporine plus mirikizumab, and ultimately blinatumomab. Blinatumomab treatment did result in disease activity dropping considerably after two doses, but it rebounded after three months and didn't respond to a third dose.
Market Data 
Markets 
AI
